Abiopharma

News list

(90% Positive) HUTCHMED DRC (HCM) Announces Clinical Development Update (Form 6-K)

Full text

News bot Oct. 18, 2025, 5:54 p.m.
🌍 HUTCHMED DRC (HCM) - Form 6-K Filing

Filing Date: 2022-07-13

Accepted: 2022-07-13 07:19:05

Event Type: Clinical Trial Update

Event Details:

First presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung cancer (WCLC), taking place August 6-9 in Vienna, Austria. Savolitinib in combination with AstraZenecas TAGRISSO (osimertinib) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients.
💼 Business Developments:
- ✅ Partnership/Collaboration
- ✅ Acquisition Activity
- ✅ Licensing Agreement
- ✅ Regulatory Milestone
- ❌ Leadership Updates: Not reported
📞 Contact Information:
- Email: bmiles@troutgroup.comEurope